Biological Information
Background Information:
Ibrutinib (PCI-32765, Imbruvica) is an FDA approved drug that targets B-cell malignancies and is approved for treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. Ibrutinib is an orally-bioavailable compound that is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Also inhibits YES and other SRC family tyrosine kinases. Provided as 5 mg of dry powder.
Usage
Product Type:
Control Ligands & Inhibitors
Application:
Drug Discovery & Development
Storage Conditions:
Store at -20°C. Please avoid multiple freeze/thaw cycles.
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Additional Information
Brand:
Eurofins DiscoverX®